Teacher Retirement System of Texas Buys 64,440 Shares of Bristol Myers Squibb Company $BMY

Teacher Retirement System of Texas lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,039,588 shares of the biopharmaceutical company’s stock after purchasing an additional 64,440 shares during the quarter. Teacher Retirement System of Texas owned about 0.05% of Bristol Myers Squibb worth $48,123,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares in the last quarter. GAMMA Investing LLC lifted its position in Bristol Myers Squibb by 18.8% in the 1st quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company’s stock valued at $2,420,000 after acquiring an additional 6,267 shares in the last quarter. Guardian Asset Advisors LLC bought a new position in Bristol Myers Squibb in the 1st quarter valued at about $204,000. Aljian Capital Management LLC lifted its position in Bristol Myers Squibb by 29.4% in the 1st quarter. Aljian Capital Management LLC now owns 20,866 shares of the biopharmaceutical company’s stock valued at $1,273,000 after acquiring an additional 4,745 shares in the last quarter. Finally, Sovran Advisors LLC lifted its position in Bristol Myers Squibb by 39.4% in the 1st quarter. Sovran Advisors LLC now owns 6,839 shares of the biopharmaceutical company’s stock valued at $417,000 after acquiring an additional 1,932 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $43.84 on Monday. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33. The company’s 50 day moving average price is $45.75 and its two-hundred day moving average price is $47.05. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a market cap of $89.24 billion, a P/E ratio of 17.68, a P/E/G ratio of 2.29 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter last year, the firm earned $2.07 EPS. The company’s quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 100.00%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.09% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BMY has been the topic of several recent research reports. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $57.23.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.